ATE361316T1 - Kristallstruktur einer deacetylase und deren inhibitoren - Google Patents

Kristallstruktur einer deacetylase und deren inhibitoren

Info

Publication number
ATE361316T1
ATE361316T1 AT00968344T AT00968344T ATE361316T1 AT E361316 T1 ATE361316 T1 AT E361316T1 AT 00968344 T AT00968344 T AT 00968344T AT 00968344 T AT00968344 T AT 00968344T AT E361316 T1 ATE361316 T1 AT E361316T1
Authority
AT
Austria
Prior art keywords
hdlp
structural information
present
deacetylase
dimensional structural
Prior art date
Application number
AT00968344T
Other languages
English (en)
Inventor
Nikola Pavletich
Michael Finnin
Jill Donigian
Victoria Richon
Richard A Rifkind
Paul A Marks
Ronald Breslow
Original Assignee
Sloan Kettering Inst Cancer
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer, Univ Columbia filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE361316T1 publication Critical patent/ATE361316T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00968344T 1999-09-08 2000-09-08 Kristallstruktur einer deacetylase und deren inhibitoren ATE361316T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15275399P 1999-09-08 1999-09-08

Publications (1)

Publication Number Publication Date
ATE361316T1 true ATE361316T1 (de) 2007-05-15

Family

ID=22544290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00968344T ATE361316T1 (de) 1999-09-08 2000-09-08 Kristallstruktur einer deacetylase und deren inhibitoren

Country Status (8)

Country Link
US (3) US7124068B2 (de)
EP (1) EP1212357B1 (de)
JP (1) JP2003518923A (de)
AT (1) ATE361316T1 (de)
CA (1) CA2383885A1 (de)
DE (1) DE60034688T2 (de)
ES (1) ES2287033T3 (de)
WO (1) WO2001018045A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
ATE361316T1 (de) * 1999-09-08 2007-05-15 Sloan Kettering Inst Cancer Kristallstruktur einer deacetylase und deren inhibitoren
WO2002102984A2 (en) 2001-06-14 2002-12-27 Sloan-Kettering Institute For Cancer Research Hdac9 polypeptides and polynucleotides and uses thereof
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
WO2003032921A2 (en) 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
AU2003220119A1 (en) 2002-03-07 2003-09-22 University Of Delaware Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006122319A2 (en) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
BRPI0613429A2 (pt) * 2005-07-14 2009-02-10 Takeda San Diego Inc inibidores de histona desacetilase
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP2079462A4 (de) * 2006-09-28 2009-12-02 Merck & Co Inc Pharmazeutische zusammensetzungen von hdac-hemmern und chelierbaren metallverbindungen und metallo-hdac-hemmer-chelat-komplexen
WO2009137503A1 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Hdac inhibitors and uses thereof
WO2009137499A1 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Inhibitors of histone deacetylase
EP2285376A4 (de) * 2008-05-16 2011-07-20 Chipscreen Biosciences Ltd 6-aminonicotinamidderivate als wirksame und selektive histondeacetylasehemmer
AU2010313255B2 (en) 2009-10-30 2015-04-30 Massachusetts Institute Of Technology The use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US8981084B2 (en) 2010-01-13 2015-03-17 Tempero Pharmaceuticals, Inc. Oxadiazole HDAC inhibitors
US20120322827A1 (en) * 2010-01-13 2012-12-20 Erkan Baloglu Compounds and methods
AU2011205283B2 (en) * 2010-01-13 2014-07-10 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013009810A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009812A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc Methods of treatment
WO2013009830A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009827A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2015051035A1 (en) 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5550316A (en) 1991-01-02 1996-08-27 Fox Chase Cancer Center Transgenic animal model system for human cutaneous melanoma
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5780594A (en) * 1993-03-01 1998-07-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Biologically active protein fragments containing specific binding regions of serum albumin or related proteins
EP0791061A4 (de) 1994-03-04 1998-07-15 Ludwig Inst Cancer Res Tiere mit gezielter genunterbrechung
US5698764A (en) 1994-06-09 1997-12-16 The Regents Of The University Of California Transgenic mice expressing HPV early region oncogene develop progressive epithelial neoplasia
US5709844A (en) 1994-06-09 1998-01-20 The Regents Of The University Of California Transgenic mice expressing HPV early region oncogene develop progressive cervico-vaginal neoplasia
JP2714537B2 (ja) * 1994-08-17 1998-02-16 コナミ株式会社 ゲーム機の昇降装置
US5919940A (en) 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5917090A (en) 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
US5811634A (en) 1995-09-12 1998-09-22 Thomas G. O'Brien Transgenic mammal encoding ornithine decarboxylase
JPH09185385A (ja) * 1995-11-02 1997-07-15 Victor Co Of Japan Ltd 音楽情報の記録方法及び再生方法並びに音楽情報再生装置
ATE361316T1 (de) * 1999-09-08 2007-05-15 Sloan Kettering Inst Cancer Kristallstruktur einer deacetylase und deren inhibitoren

Also Published As

Publication number Publication date
US20070087427A1 (en) 2007-04-19
WO2001018045A9 (en) 2002-11-07
EP1212357B1 (de) 2007-05-02
DE60034688D1 (de) 2007-06-14
US20070100559A1 (en) 2007-05-03
CA2383885A1 (en) 2001-03-15
ES2287033T3 (es) 2007-12-16
US20030013176A1 (en) 2003-01-16
DE60034688T2 (de) 2008-01-17
EP1212357A4 (de) 2004-03-17
WO2001018045A1 (en) 2001-03-15
JP2003518923A (ja) 2003-06-17
EP1212357A1 (de) 2002-06-12
US7124068B2 (en) 2006-10-17

Similar Documents

Publication Publication Date Title
ATE361316T1 (de) Kristallstruktur einer deacetylase und deren inhibitoren
WO2004005513A3 (en) Methods for specifically inhibiting histone deacetylase-7 and 8
EA200100812A1 (ru) АЦЕТИЛЕНОВЫЕ, ОСНОВАННЫЕ НА α-АМИНОКИСЛОТАХ, ПРОИЗВОДНЫЕ СУЛЬФОНАМИДОВ ГИДРОКСАМОВЫХ КИСЛОТ - ИНГИБИТОРЫ ФЕРМЕНТОВ, КОНВЕРТИРУЮЩИХ ФАКТОР НЕКРОЗА ОПУХОЛЕЙ TNF-α (TACE)
NO985376L (no) Kinolinkarboksamider som TNF-inhibitorer og som PDA-IV inhibitorer
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
DE69609957D1 (de) Succinamid-derivate und ihre verwendung als metalloproteinaseinhibitoren
DE69717474T2 (de) Durch cyclische aminosäuren oder cyclische hydroxysäuren substituierte benzamidinderivate und deren verwendung als antikoagulantien
EA200000652A1 (ru) Кристаллы глюкагоноподобного пептида 1
DE69226182T2 (de) Stabilisierte enzyme und waschmittelzusammensetzungen
BRPI0414792A (pt) derivados de ácido 4-(1h-indol-3-il-metilidenoaminóxi-propóxi)-benzóico e compostos relacionados como inibidores de pai-1 para o tratamento de enfraquecimento do sistema fibrinolìtico e de trombose
PT689459E (pt) Novo agente para o controlo da actividade celular
BR0007035A (pt) Métodos de controle de pragas de agrótis
DE69821376D1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
BR9610922A (pt) Peptìdios rio-substituìdos como inibidores para metalo-proteinases e liberação de tnf
HUP0100668A2 (hu) Virulenciával kapcsolatos nukleinsavszekvenciák és alkalmazásuk
NO972313L (no) Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav
EA200100807A1 (ru) Производные алкинилсодержащих гидроксамовых кислот и их применение в качестве ингибиторов tace
SE0202157D0 (sv) Methods for identification of compounds modulating insulin resistance
ATE340257T1 (de) Histonedeacetylase 9
FI955642A0 (fi) 4-amino-17beta-(syklopropyylioksi)androst-4-en-3-oni, 4-amino-17beta-(syklopropyliamino)androst-4-en-3-oni ja näitä muistuttavat yhdisteet C17-20-lyaasin ja 5alfa-reduktaasin inhibiittoreina
DE50211985D1 (de) Verwendung von pyridin-2,4-dicarbons urediamiden und pyrimid in-4,6-dicarbons urediamiden zur selektiven inhibierung von kollagenasen
BR0213779A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
BRPI0610824A8 (pt) Compostos derivados de purina, uso dos mesmos e composição contendo os referidos compostos
HUP0301089A2 (hu) Dermális alkalmazási rendszerek aminolevulinsavhoz
DE60015098D1 (de) 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties